Ethyl α-ethyl-γ,γ-dimethylacetoacetat | 54285-47-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: Ethyl α-ethyl-γ,γ-dimethylacetoacetat
• 英文别名: Ethyl 2-ethyl-4-methyl-3-oxopentanoate
• CAS: 54285-47-1
• 化学式: C₁₀H₁₈O₃
• mdl: MFCD00511277
• 分子量: 186.251
• InChiKey: OQONSHOKYQHQLT-UHFFFAOYSA-N

物化性质

• 沸点：
  105-107 °C(Press: 18 Torr)
• 密度：
  0.9480 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl α-ethyl-γ,γ-dimethylacetoacetat 在 sodium hydroxide 作用下， 生成 2-甲基-3-己酮
  参考文献：
  名称：

  Acyl Exchanges between Esters and 1,3-Diketones and β-Keto-esters

  摘要：

  DOI：

  10.1021/ja01853a047
• 作为产物：
  描述：

  碘乙烷 、 异丁酰乙酸乙酯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 0.5h， 以90%的产率得到Ethyl α-ethyl-γ,γ-dimethylacetoacetat
  参考文献：
  名称：

  MRGX Receptor Antagonists

  摘要：

  该发明涉及一种用于预防或治疗与MrgX2受体相关的疾病或紊乱的方法。该发明还涉及MrgX2拮抗剂及其生理上可接受的盐。该发明还涉及包含MrgX2拮抗剂的药物组合物和剂型。

  公开号：

  US20210128561A1

文献信息

• Reactivity of ambident anions—II
  作者：A.L. Kurts、P.I. Dem'yanov、A. Macias、I.P. Beletskaya、O.A. Reutov

  DOI：10.1016/s0040-4020(01)98182-7

  日期：1971.1

  same solvent was measured by the conductometric method. The rates of both O- and C-ethylations of the enolate ion were measured. The pKa of the corresponding β-ketoesters were measured in DMF. The reactivity of the enolates investigated was found to be proportional to their basicity.

  报道了HMPT中甲苯磺酸乙酯对γ，γ-二甲基-乙基，γ-γ，γ-γ-三甲基乙酰乙酸的K-和Cs-烯酸酯的烷基化以及γ，γ，γ-三氟乙酰乙酸乙酯的Cs-烯酸酯。通过电导法测量在相同溶剂中β-酮酸酯Cs-烯酸酯的解离度。测量了烯醇盐离子的O-和C-乙基化的速率。在DMF中测量相应的β-酮酸酯的p Ka。发现所研究的烯醇化物的反应性与其碱性成正比。
• Copper(II) Triflate Catalyzed Amination and Aziridination of 2-Alkyl Substituted 1,3-Dicarbonyl Compounds
  作者：Thi My Uyen Ton、Ciputra Tejo、Diane Ling Ying Tiong、Philip Wai Hong Chan

  DOI：10.1021/ja301415k

  日期：2012.5.2

  A method to prepare alpha-acyl-beta-amino acid and 2,2-diacyl aziridine derivatives efficiently from Cu(OTf)(2) + 1,10-phenanthroline (1,10-phen)-catalyzed amination and aziridination of 2-alkyl substituted 1,3-dicarbonyl compounds with PhI=NTs is described. By taking advantage of the orthogonal modes of reactivity of the substrate through slight modification of the reaction conditions, a divergence in product selectivity was observed. In the presence of 1.2 equiv of the iminoiodane, amination of the allylic C-H bond of the enolic form of the substrate, formed in situ through coordination to the Lewis acidic metal catalyst, was found to selectively occur and give the beta-aminatecl adduct. On the other hand, increasing the amount of the nitrogen source from 1.2 to 2-3 equiv was discovered to result in preferential formal aziridination of the C-C bond of the 2-alkyl substituent of the starting material and formation of the aziridine product.
• Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5
  作者：Guan Wang、Zheng Liu、Tiantian Chen、Zhen Wang、Huaiyu Yang、Mingyue Zheng、Jing Ren、Guanghui Tian、Xiaojun Yang、Li Li、Jianfeng Li、Jin Suo、Rongxia Zhang、Xiangrui Jiang、Nicholas Kenneth Terrett、Jingshan Shen、Yechun Xu、Hualiang Jiang

  DOI：10.1021/jm301159y

  日期：2012.12.13

  Cyclic nucleotide phosphodiesterase type 5 (PDES) is a prime drug target for treating the diseases associated with a lower level of the cyclic guanosine monophosphate (cGMP), which is a specific substrate for PDE5 hydrolysis. Here we report a series of novel PDE5 inhibitors with the new scaffold of the monocyclic pyrimidin-4(3H)-one ring developed using the structure-based discovery strategy. In total, 37 derivatives of the pyrimidin-4(3H)-ones, were designed, synthesized, and evaluated for their inhibitory activities to PDES, resulting in 25 compounds with IC50 ranging from 1 to 100 nM and 11 compounds with IC50 ranging from 1 to 10 nM. Compound 5, 5,6-diethyl-2[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one, the most potent compound, has an excellent IC50 (1.6 nM) in vitro and a good efficacy in a rat model of erection. It thus provides a potential candidate for the further development into a new drug targeting PDE5.